MIR

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Mirion Technologies stock presents a clear valuation split. The intrinsic value estimate based on a Discounted Cash Flow (DCF) approach points to the shares trading below that estimate, while market multiples suggest the stock is priced on the richer side, and the broader valuation checks lean that way too. Mirion Technologies has delivered a 78.2% gain over the past 3 years, which makes the current valuation especially important for investors thinking about what comes next. The investment case can benefit if Mirion Technologies converts more of its revenue into steady cash flows, while any sign of weaker profitability or heavier capital requirements may weigh on what investors are willing to pay. On Simply Wall St's broader checks, Mirion Technologies scores 2 out of 6 on valuation, which points to a stock that does not screen as an obvious bargain on most measures despite the Discounted Cash Flow (DCF) upside. The issue now is whether that mix of Discounted Cash Flow (DCF) upside, a low overall value score and richer market multiples still leaves enough room for a patient investor in Mirion Technologies. Find out why Mirion Technologies' -29.1% return over the last year is lagging behind its peers. The Discounted Cash Flow (DCF) model values Mirion Technologies by projecting future cash the business could return to shareholders and discounting it back to today. For Mirion Technologies, the latest twelve month free cash flow is about $125.3 million, which the model treats as growing over time rather than shrinking. On those assumptions, the DCF points to an estimated intrinsic value of about $16.48 per share. That sits above the current share price, which implies a discount of roughly 10.9%. The key swing factor is whether Mirion Technologies can sustain and build on its current cash generation so that future free cash flow tracks the growth profile used in the model. On this DCF view, Mirion Technologies stock currently appears undervalued relative to the market price. Our Discounted Cash Flow (DCF) analysis suggests Mirion Technologies is undervalued by 10.9%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks. Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Mirion Technologies. P/E is a useful cross check for Mirion Technologies because earnings are a key anchor for how much investors are willing to pay per share. On this measure, the stock trades on a P/E of about 145.8x, which is well above the electronic industry average of 31.0x and also higher than the peer average of 22.1x. The fair P/E ratio from the model is 57.3x, which already factors in Mirion Technologies' sector, size and risk profile. The gap between that fair level and the current 145.8x suggests that investors are paying a rich premium for the stock on earnings, even after adjusting for those characteristics. On the P/E multiple, Mirion Technologies stock currently screens as clearly overvalued relative to both peers and the modelled fair ratio. See what the numbers say about this price — find out in our valuation breakdown. Simply Wall St Narratives take this valuation split for Mirion Technologies and outline which potential paths for growth, margins and earnings would need to occur for the stock to be worth significantly more or less than today’s price on the Community page. Each narrative treats Mirion Technologies' fair value as a thesis about how the business might develop over time, so you can track how that view holds up as new information arrives. You can add your voice to the Mirion Technologies story by sharing a Narrative that sets out your number driven view on where its growth, margins and execution go from here. Put your thesis on record and track how it holds up as new results and updates come through. Do you think there's more to the story for Mirion Technologies? Head over to our Community to see what others are saying! Mirion Technologies sits between an intrinsic value view that flags some undervaluation and market multiples that point to an overvalued stock. The Discounted Cash Flow (DCF) estimate leans on the company converting current cash generation into durable free cash flow, while the richer P/E multiple reflects strong expectations and sentiment compared with peers. Broader checks are not especially supportive. The key question is whether Mirion Technologies can keep improving cash flow and profitability enough to justify that premium, rather than leaving the apparent discount as a value trap. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include MIR. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Interested in Mirion Technologies, Inc.? Here are five stocks we like better. Q2 revenue rose 19.7% to $266.8 million, driven primarily by acquisitions, while organic growth was 1%. Adjusted EBITDA increased 27.5% to $65 million, and the margin expanded by 150 basis points. Nuclear demand strengthened significantly: orders rose 40% to $291 million, SMR orders reached $49 million, and backlog exceeded $1.1 billion. Management cited robust installed-base and advanced-reactor activity and expects stronger performance in the second half. Mirion reiterated its full-year guidance despite a canceled Chinese new-build order and weaker medical hardware demand. The company generated $49 million in second-quarter adjusted free cash flow and repurchased approximately $25 million of shares. Mirion Technologies (NYSE:MIR) reported second-quarter revenue growth of nearly 20%, driven largely by acquisitions, while organic growth remained modest and the company maintained its full-year outlook on expectations for a stronger second half. Second-quarter revenue rose 19.7% year over year to $266.8 million. Acquisitions, primarily Paragon, accounted for about 18 percentage points of that growth, while organic revenue increased 1%, in line with management’s April expectations. Adjusted EBITDA increased 27.5% to $65 million, and the adjusted EBITDA margin expanded 150 basis points, supported by pricing and favorable product mix. → Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? Chairman and CEO Tom Logan said rising orders and backlog, along with margin expansion in both operating segments, position the company for an acceleration in the second half of 2026. “We’re maintaining our 2026 full-year guidance, which implies a meaningful step-up in financial performance for the remainder of the year,” Logan said. Second-quarter orders increased 40% to $291 million including a $62 million contribution from Paragon and Certrec. Before acquisitions, core orders rose 10%. The company said nuclear power orders, excluding M&A, grew about 50%, with growth split between demand from the operating nuclear fleet and small modular reactor, or SMR, projects. → Why SK hynix Could Be the Best AI Chip Stock to Buy Now Mirion booked $49 million in SMR orders during the quarter, up $42 million from a year earlier. The company’s backlog exceeded $1.1 billion at quarter-end, nearly 40% higher than a year ago. Legacy backlog, excluding additions from Paragon and Certrec, was up 17%, while the legacy installed-base portion of backlog rose nearly 40% year over year. Logan said the company sees several sources of demand from the existing nuclear fleet, including catch-up spending on deferred maintenance, plant life extensions and upgrades, and digital transformation initiatives. He noted that roughly 80% of Mirion’s nuclear-power revenue is tied to the installed base, producing recurring and repeat business. → 3 Value ETFs to Consider as Growth Stocks Lag Behind Management also cited policy, financing and project developments supporting the nuclear market, including U.S. regulatory proposals intended to streamline licensing, a Department of Energy loan program for reactor construction, and activity in advanced reactor designs. Logan said Mirion, Paragon and Certrec participated in each of four advanced reactor designs that reached criticality under the DOE reactor pilot program. Mirion said it won several large opportunities during the second quarter, including a previously disclosed Paragon SMR order, a second portion of another SMR order, and a portion of a radioactive-waste-handling order in its defense and diversified end market. During the first two weeks of July, the company received more than $50 million of large orders, including a European installed-base order and a U.S. Department of Energy order. Those July awards were partly offset by the cancellation of a Chinese new-build order originally booked in 2019. The associated sites had made little progress amid geopolitical tensions, according to management. The cancellation had no impact on 2026 guidance and only an immaterial effect on Mirion’s long-range guidance, CFO and Medical Group President Brian Schopfer said. Logan said Mirion does not view the cancellation as signaling broader backlog risk. He said the company remains active in China’s installed base, serving 50 of the country’s 60 operating reactors, and has continued to generate a predictable spare-parts business there. However, he acknowledged that the company has no content in China’s indigenous Hualong reactor program. Mirion had approximately $160 million of large opportunity awards year to date and about $280 million of opportunities remaining. Management characterized its screening methodology as opportunities above $10 million where it sees a greater-than-50% probability of winning, while emphasizing that timing remains the primary risk. Nuclear and Safety revenue increased 31% to $186 million, including 2.3% organic growth. Paragon revenue increased 15% in the quarter and 27% year to date. Nuclear and Safety adjusted EBITDA rose 35% to $51 million, while the segment margin expanded about 70 basis points. Favorable European product mix, cost control and a modest U.S. tariff refund helped offset dilution from the Paragon acquisition. Although nuclear power orders were strong, organic revenue in that end market was flat, as growth in installed-base and SMR activity was offset by lower new-build revenue. Schopfer said new-build revenue can be uneven based on project timing, but Mirion continues to expect double-digit organic revenue growth in nuclear power for the full year. Medical segment revenue declined 1% to $81 million, with organic revenue also down 1%. Revenue in radiation therapy quality assurance, or RTQA, continued to grow, but nuclear medicine revenue declined because of delayed hardware demand, and dosimetry faced a difficult comparison with a large prior-year hardware order. Mirion raised its full-year RTQA organic-growth outlook to double digits from a prior expectation of mid-single-digit-plus growth. The company reduced its nuclear medicine outlook to mid-single-digit growth from a prior double-digit forecast, citing delayed hardware demand that it views as a delay rather than a demand decline. Dosimetry organic revenue is now expected to decline for the year, compared with a prior forecast for flat performance, due to lower hardware revenue and difficult comparisons. Despite the revised end-market assumptions, management said these changes largely offset one another and reiterated full-year Medical segment guidance. Mirion generated $49 million in adjusted free cash flow during the quarter and $60 million in the first half, which Schopfer called the company’s best first-half adjusted free-cash-flow performance since going public. The company attributed the result to higher adjusted EBITDA, working-capital performance, lower cash taxes and refinancing-related benefits. The company repurchased about 1.4 million shares for approximately $25 million in the second quarter. Year-to-date repurchases totaled roughly $40 million, leaving $40 million authorized under the current program. Management said approximately 81% of expected full-year revenue is covered by first-half results and backlog expected to convert during the second half, comparable with prior years. For the third quarter, Mirion expects high-single-digit consolidated organic revenue growth, including mid-single-digit growth in Nuclear and Safety and high-single-digit growth in Medical. Consolidated adjusted EBITDA margin is expected to expand year over year, although Nuclear and Safety margins are expected to contract because of Paragon dilution, incentive-compensation comparisons and a greater mix of lower-margin new-build revenue. Mirion Technologies Inc (NYSE: MIR) is a leading global provider of radiation detection, measurement and monitoring solutions. The company's portfolio includes instrumentation, software and service offerings designed to detect, quantify and manage radiation in nuclear power, oil and gas, defense and homeland security, medical imaging and diagnostic applications. Mirion's product suite spans personal and environmental dosimetry, area monitors, digital imaging detectors and turnkey solutions for decommissioning and environmental remediation projects. Mirion traces its origins to the combination of several established radiation measurement businesses, including the former Canberra nuclear instrumentation division, and has been supported by private equity investors before completing its initial public offering on the New York Stock Exchange in 2023. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Mirion Technologies Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for July 2026.

This article first appeared on GuruFocus. Release Date: July 29, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Mirion Technologies Inc (NYSE:MIR) reported a 20% increase in total revenue for the second quarter, with organic revenue growth of 1%, aligning with expectations. The company demonstrated expanding adjusted EBITDA margins, with a 27.5% increase compared to last year, driven by favorable product mix and pricing. Mirion Technologies Inc (NYSE:MIR) maintained its full-year guidance, indicating confidence in a strong financial performance for the remainder of the year. The nuclear power segment showed robust growth, with orders up 50% excluding M&A, highlighting strong demand in the nuclear power market. The company is actively investing in AI to accelerate product development, improve organizational efficiencies, and create AI-powered solutions, positioning itself for future growth. Organic revenue growth was only 1%, which is relatively low compared to the total revenue increase, indicating reliance on acquisitions for growth. The medical segment experienced a 1% decline in revenue, with nuclear medicine and dosimetry markets underperforming due to delayed hardware demand. A cancellation of a Chinese new build order from 2019 impacted the order book, although it was noted to have no effect on 2026 guidance. The company faces challenges in maintaining its 30% EBITDA margin target for 2028, with current margins at 25.6% and requiring significant improvement. There is a risk of timing delays in large opportunity pipelines, which could impact the realization of expected revenue growth. Warning! GuruFocus has detected 5 Warning Sign with MIR. Is MIR fairly valued? Test your thesis with our free DCF calculator. Q: Can you provide more details on the large opportunity pipeline and how much of it is likely to be secured by Mirion? A: Tom Logan, CEO: We believe we have a strong chance of winning these opportunities, as they are projects over $10 million where we estimate a greater than 50% probability of success. Historically, we have won all opportunities that have traded in the last quarter. The main risk is timing, but the opportunity set continues to grow. Q: How confident are you in achieving the implied mid-teens organic growth in Q4, and how much of this is already in backlog? A: Brian Shotfer, CFO: We have good visibility with 81% of our expected full-year revenue accounted for, similar to previous years. We have orders to win and execution to complete, but we feel confident given our current position and the orders won in early July. Q: Can you explain the recent debooking of the Chinese contract and its implications for your backlog? A: Tom Logan, CEO: The debooking was due to a lack of progress on the project and changing US-China trade dynamics. We continuously scrutinize our backlog and believe its quality remains high. We do not see this as indicative of broader issues. Q: What is the outlook for Small Modular Reactors (SMRs) and their contribution to revenue? A: Tom Logan, CEO: We are seeing increasing momentum and opportunities in the SMR sector. While we are cautious about timelines, the growth opportunity is significant, and we expect SMR revenue to grow faster than our overall organic growth rate. Q: What caused the reduced hardware volume in nuclear medicine, and what gives you confidence in a pickup in the second half? A: Brian Shotfer, CFO: There was a pause in the first half, but we expect momentum to return with strong order growth in nuclear medicine software. Our factory improvements have reduced lead times, enhancing our ability to book and ship efficiently. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Double-digit order growth is fueling a record $1.1 billion backlog, driven by a 'nuclear super trend' and regulatory streamlining in North America. Nuclear power demand is manifesting in three waves: catch-up capital spending for deferred maintenance, life extensions triggering system upgrades, and digital transformation to capture aging workforce expertise. Adjusted EBITDA margin expansion of 150 basis points was achieved through favorable product mix and pricing, which successfully offset inflationary headwinds and M&A dilution. The acquisition of Paragon and Certrec has strategically positioned the company to capture outsized demand from the North American nuclear installed base and emerging SMR projects. Management is implementing a three-pillar AI strategy focused on accelerating software development cycles, automating back-office processes, and launching AI-powered dosimetry solutions. Legacy backlog growth of 17% (31% in nuclear power) validates the foundational demand from existing reactors, which provide approximately 80% of nuclear power revenue. Full-year 2026 guidance is maintained, supported by 81% revenue visibility through first-half results and existing backlog scheduled for second-half conversion. Organic revenue growth is expected to accelerate to between 7.5% and 11.2% in the second half, driven by nuclear power and RTQA end-markets. Second-half adjusted EBITDA margins are projected to reach 27% to 29% as operating leverage and procurement efficiencies take effect. Management anticipates ending the year with approximately 2.5x leverage, assuming no further M&A activity, while prioritizing strategic acquisitions in the pipeline. The SMR opportunity set is expected to grow faster than the overall organic rate, with momentum shifting 'to the left' as commercial deployment timelines accelerate. A $18 million Chinese new build order from 2019 was debooked due to geopolitical tensions and lack of project progress, though management views this as an isolated event. Medical segment guidance was adjusted to reflect delayed hardware demand in nuclear medicine and tough comparables in dosimetry, though RTQA outlook was raised to double-digits. A restructuring reserve was taken in Q2 to optimize organizational spans and layers, which is expected to provide margin benefits starting in 2027. Management noted a $5 million annual spend on AI infrastructure and engineering as a necessary investment for long-term productivity and product differentiation. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management applies a screening methodology requiring a greater than 50% 'right to win' probability for projects over $10 million. The primary risk identified is timing, as large projects often shift to the right, though the overall opportunity set is replenishing and building. The target remains intact despite M&A dilution, with 50% of the improvement expected from operating leverage as top-line growth outpaces fixed costs. Additional gains are expected from procurement efficiencies (1-2 points) and internal productivity improvements driven by the Mirion Business System and AI. Management views the data center build-out as 'upside optionality' rather than a core dependency. The fundamental driver is the binary decision by operators to extend plant lives by 20 years, which triggers mandatory system replacement cycles regardless of data center growth rates. The first-half pause was attributed to customers waiting for momentum in the drug pipeline, but strong double-digit software order growth suggests underlying health. Improved factory lead times following ERP implementation and consolidation allow for faster 'book-and-ship' execution in the second half.

Revenues for the second quarter increased 19.7% to $266.8 million, compared to $222.9 million in the same period in 2025. GAAP net income was $8.1 million in the second quarter, a 4.7% decrease compared to GAAP net income of $8.5 million in the same period in 2025; Adjusted EBITDA was $65.3 million in the second quarter, a 27.5% increase from $51.2 million in the same period last year. GAAP net earnings per share in the second quarter was $0.03, compared to $0.04 in the same period in 2025. Adjusted earnings per share for the quarter was $0.12, compared to $0.11 in the same period in 2025. The current period calculation of Adjusted EPS includes stock based compensation expense. Second quarter orders, excluding Paragon & Certrec acquisitions, were $229 million, a 10% increase from $208 million in the same period last year. Including Paragon and Certrec acquisitions, second quarter orders were $291 million, a 40% increase compared to the same period last year. The company reaffirmed 2026 total revenue growth, Organic Revenue growth, Adjusted EBITDA, Adjusted Free Cash Flow, and Adjusted EPS guidance for the fiscal year ending December 31, 2026. ATLANTA, July 28, 2026--(BUSINESS WIRE)--Mirion ("we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, today announced results for the second quarter ended June 30, 2026. "Our second quarter performance reflects margin expansion across both operating segments, increased adjusted free cash flow, and continued orders and backlog growth," commented Mirion’s Chairman and Chief Executive Officer Thomas Logan. "We captured several large opportunity orders in the second quarter with substantial opportunity available for the rest of the year." Logan continued, "Our acquisitions of Certrec and Paragon have augmented our ability to capitalize on growing nuclear power opportunities in North America. Moreover, our global presence puts us at the forefront of international nuclear growth ambitions." 2026 Guidance Commenting on Mirion’s full year 2026 guidance, Logan said, "We remain well-positioned for second half 2026 accelerated revenue growth, adjusted free cash flow, and margin expansion. We are maintaining our full year 2026 guidance while adjusting the end-market composition of our Medical segment." Mirion reaffirmed 2026 total revenue growth, Organic Revenue growth, Adjusted EBITDA, Adjusted Free Cash Flow, and Adjusted EPS guidance for the fiscal year ending December 31, 2026. Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds. Organic Revenue growth of approximately 5.0% – 7.0%. Adjusted EBITDA and Adjusted EBITDA margin of approximately $285 million – $300 million; Adjusted EBITDA margin of approximately 25.0% – 26.0%. Adjusted Free Cash Flow of approximately $155 million – $175 million; Adjusted Free Cash Flow Conversion of approximately 54% – 58% of Adjusted EBITDA. Adjusted EPS of approximately $0.48 – $0.55 per share. Additional modeling and guidance assumptions are included in the appendix of the earnings presentation on the Company’s investor relations page. The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading "Forward-Looking Statements." In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for Organic Revenue growth, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, Adjusted Free Cash Flow and Adjusted Free Cash Flow conversion are not available without unreasonable effort. Conference Call Mirion will host a conference call tomorrow, July 29, 2026 at 10:00 a.m. ET to discuss its financial results. Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call. A live webcast will also be available at https://ir.mirion.com/news-events. A telephonic replay will be available shortly after the conclusion of the call and until August 12, 2026. Participants may access the replay at 1-844-512-2921 or 1-412-317-6671, and enter access code 13761513. An archived replay of the call and an accompanying presentation will also be available on the Investors section of the Mirion website at https://ir.mirion.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipate", "believe", "continue", "could", "estimate", "expect", "hope", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "should", "strive", "seeks", "would", "will", "understand" and similar words are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward looking. These forward-looking statements include but are not limited to, statements regarding our future operating results, financial position and guidance, our backlog and order potential, our business strategy and plans, our objectives for future operations, macroeconomic trends, trends in cancer care, nuclear power and small modular reactor industries, foreign exchange, interest rate and inflation expectations and any future mergers, acquisitions, divestitures and strategic investments, including the completion and integration of previously completed transactions. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including changes in domestic and foreign business, market, economic, financial, political and legal conditions, including related to matters affecting Russia, the relationship between the United States and China, conflict, hostilities or geopolitical instability in the Middle East (including the U.S.-Israel-Iran conflict), tariffs, sanctions, export controls, trade restrictions or other trade and supply chain disruptions, and risks of slowing economic growth or economic recession in the United States and globally; developments in the government budgets (defense and non-defense) in the United States and other countries, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, delays in the government budget process, a U.S. government shutdown or the U.S. government’s failure to raise the debt ceiling; risks related to the public’s perception of nuclear radiation and nuclear technologies; risks related to the continued growth of our end markets and timing of customer capital spending, procurement timing and project schedules; our ability to win new customers and retain existing customers; our ability to realize sales expected from our backlog of orders and contracts; risks related to governmental contracts; our ability to mitigate risks associated with long-term fixed price contracts, including risks related to inflation; risks related to information technology system failures or other disruptions or cybersecurity, data security or other security threats, including risks related to the implementation and enhancement of information systems and emerging technologies such as artificial intelligence; our ability to manage our supply chain or difficulties with third-party manufacturers; risks related to competition; our ability to manage disruptions of, or changes in, our independent sales representatives, distributors and original equipment manufacturers; our ability to realize the expected benefit from strategic transactions, such as acquisitions, divestitures, investments and partnerships, including any synergies, or internal restructuring and improvement efforts; our ability to issue debt, equity or equity-linked securities in the future; risks related to changes in tax law and ongoing tax audits; risks related to future legislation and regulation both in the United States and abroad; risks related to the costs or liabilities associated with product liability claims; risks related to the uncertainty of legal claims, litigation, arbitration and similar proceedings; our ability to attract, train and retain key members of our leadership team and other qualified personnel; risks related to the adequacy of our insurance coverage; risks related to the global scope of our operations, including operations in international and emerging markets; risks related to our exposure to fluctuations in foreign currency exchange rates, interest rates and inflation, including the impact on our debt service costs; our ability to comply with various laws and regulations and the costs associated with legal compliance; risks related to the outcome of any litigation, government and regulatory proceedings, investigations and inquiries; risks related to our ability to protect or enforce our proprietary rights on which our business depends or third-party intellectual property infringement claims; liabilities associated with environmental, health and safety matters; our ability to predict our future operational results; and the effects of health epidemics, pandemics and similar outbreaks may have on our business, results of operations or financial condition. Further information on risks, uncertainties and other factors that could affect our financial results are included in the filings we make with the United States Securities and Exchange Commission (the "SEC") from time to time, including our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other periodic reports filed or to be filed with the SEC. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made. Use of Non-GAAP Financial Information In addition to our results determined in accordance with GAAP, we believe that the presentation of non-GAAP financial information provides important supplemental information to management and investors regarding financial and business trends relating to our financial condition and results of operations. For further information regarding these non-GAAP measures, including the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, please refer to the financial tables below, as well as the "Reconciliation of Non-GAAP Financial Measures" section of this press release. Non-GAAP financial information is not a substitute for GAAP financial information and undue reliance should not be placed on such non-GAAP financial information. In addition, similarly titled items used by other companies may not be comparable due to variations in how they are calculated and how terms are defined. Channels for Disclosure of Information Mirion intends to announce material information to the public through the Mirion Investor Relations website ir.mirion.com, SEC filings, press releases, public conference calls and public webcasts. Mirion uses these channels, as well as social media, to communicate with its investors, customers, and the public about the company, its offerings, and other issues. It is possible that the information Mirion posts on social media could be deemed to be material information. As such, Mirion encourages investors, the media, and others to follow the channels listed above, including the social media channels listed on Mirion’s investor relations website, and to review the information disclosed through such channels. Any updates to the list of disclosure channels through which Mirion will announce information will be posted on the investor relations page on Mirion’s website. About Mirion Mirion (NYSE: MIR) is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Nuclear & Safety group provides proven radiation safety technologies that operate with precision – for essential work within R&D labs, critical nuclear facilities, and on the front lines. The Mirion Medical group solutions help enhance the delivery and ensure safety in healthcare, powering the fields of Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry, and Diagnostic Imaging. Headquartered in Atlanta (GA – USA), Mirion employs approximately 3,200 people and operates in 12 countries. Learn more at mirion.com. Share Count 243,266,822 shares of Class A common stock were outstanding as of June 30, 2026. This excludes (1) 5,759,555 shares of Class B common stock outstanding as of June 30, 2026, (2) 911,204 shares of Class A common stock underlying restricted stock units, 2,048,413 shares of Class A common stock underlying performance stock units, and 2,500,000 shares of Class A common stock underlying performance stock options; and (3) any other shares issuable from future equity awards under our 2021 Omnibus Incentive Plan, which had 43,249,055 shares reserved (subject to annual automatic increases) as of June 30, 2026. The 5,759,555 shares of Class B common stock are paired on a one-for-one basis with shares of Class B common stock of Mirion Intermediate Co., Inc. (the "paired interests"). Holders of the paired interests have the right to have their interests redeemed for, at the option of Mirion, shares of Class A common stock on a one-for-one basis or cash based on a trailing stock price average. All share data is as of June 30, 2026, unless otherwise noted. Reconciliation of Non-GAAP Financial Measures In addition to our results determined in accordance with GAAP, we believe the following non-GAAP measures are useful in evaluating our operating performance. We use the following non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business. Organic revenues is defined as Revenues excluding the impact of foreign exchange rates as well as mergers, acquisitions and divestitures in the period. Adjusted EBITDA is defined as net income before interest expense, income tax expense, depreciation and amortization adjusted to remove the impact of foreign currency gains and losses, amortization of acquired intangible assets, changes in the fair value of warrants, certain non-operating expenses (restructuring and costs to achieve operational synergies, merger, acquisition and divestiture expenses and IT project implementation expenses), stock-based compensation expense, debt extinguishment and income tax impacts of these adjustments. Adjusted EBITDA margin is defined as Adjusted EBITDA divided by Revenue. Adjusted net income is defined as GAAP net income adjusted for foreign currency gains and losses, amortization of acquired intangible assets, changes in the fair value of warrants, certain non-operating expenses (restructuring and costs to achieve operational synergies, merger, acquisition and divestiture expenses and IT project implementation expenses), stock-based compensation expense (2025 and prior), debt extinguishment and income tax impacts of these adjustments. Adjusted EPS is defined as adjusted net income divided by weighted average common shares outstanding — basic and diluted. Adjusted Free Cash Flow is defined as free cash flow adjusted to include the impact of cash used to fund non-operating expenses. We believe that the inclusion of supplementary adjustments to free cash flow applied in presenting adjusted free cash flow is appropriate to provide additional information to investors about our cash flows that management utilizes on an ongoing basis to assess our ability to generate cash for use in acquisitions and other investing and financing activities. Adjusted Free Cash Flow Conversion is defined as adjusted free cash flow divided by adjusted EBITDA. Free cash flow is defined as U.S. GAAP net cash provided by operating activities adjusted to include the impact of purchases of property, plant, and equipment, purchases of badges and proceeds from derivative contracts. Net leverage is defined as Net Debt (debt minus cash and cash equivalents) divided by Adjusted EBITDA plus contributions to Adjusted EBITDA if acquisitions made during the applicable period had been made before the start of the applicable period. Operating Metrics Order and orders growth are defined as the amount of revenue earned in a given period and estimated to be earned in future periods from contracts entered into in a given period as compared with such amount for a prior period. Foreign exchange rates are based on the applicable rates as reported for the time period. The following tables present reconciliations of certain non-GAAP financial measures for the applicable periods. View source version on businesswire.com: https://www.businesswire.com/news/home/20260728110841/en/ Contacts For investor inquiries: Eric [email protected] For media inquiries: Erin [email protected]

Mirion Technologies, Inc. (MIR) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +20.00%. A quarter ago, it was expected that this company would post earnings of $0.1 per share when it actually produced earnings of $0.1, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Mirion Technologies, which belongs to the Zacks Technology Services industry, posted revenues of $266.8 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 1.81%. This compares to year-ago revenues of $222.9 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Mirion Technologies shares have lost about 28.1% since the beginning of the year versus the S&P 500's gain of 8.3%. While Mirion Technologies has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Mirion Technologies was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.13 on $277.48 million in revenues for the coming quarter and $0.53 on $1.14 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Technology Services is currently in the bottom 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, ZenaTech, Inc. (ZENA), is yet to report results for the quarter ended June 2026. This company is expected to post quarterly loss of $0.21 per share in its upcoming report, which represents a year-over-year change of -50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. ZenaTech, Inc.'s revenues are expected to be $6.97 million, up 330.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Mirion Technologies, Inc. (MIR) : Free Stock Analysis Report ZenaTech, Inc. (ZENA) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Coursera (COUR) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 29. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This online learning platform is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents a year-over-year change of -8.3%. Revenues are expected to be $294.06 million, up 57.2% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 2933.33% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Coursera, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%. On the other hand, the stock currently carries a Zacks Rank of #2. So, this combination makes it difficult to conclusively predict that Coursera will beat the consensus EPS estimate. Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Coursera would post earnings of $0.09 per share when it actually produced earnings of $0.07, delivering a surprise of -22.22%. Over the last four quarters, the company has beaten consensus EPS estimates two times. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Coursera doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Among the stocks in the Zacks Technology Services industry, Mirion Technologies, Inc. (MIR), is soon expected to post earnings of $0.1 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of -9.1%. This quarter's revenue is expected to be $272.14 million, up 22.1% from the year-ago quarter. The consensus EPS estimate for Mirion Technologies has been revised 1.6% higher over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +7.84%. This Earnings ESP, combined with its Zacks Rank #4 (Sell), makes it difficult to conclusively predict that Mirion Technologies will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Coursera, Inc. (COUR) : Free Stock Analysis Report Mirion Technologies, Inc. (MIR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Wall Street expects a year-over-year decline in earnings on higher revenues when Mirion Technologies, Inc. (MIR) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 28. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This company is expected to post quarterly earnings of $0.10 per share in its upcoming report, which represents a year-over-year change of -9.1%. Revenues are expected to be $272.14 million, up 22.1% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Mirion Technologies, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +7.84%. On the other hand, the stock currently carries a Zacks Rank of #4. So, this combination makes it difficult to conclusively predict that Mirion Technologies will beat the consensus EPS estimate. While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Mirion Technologies would post earnings of $0.1 per share when it actually produced earnings of $0.10, delivering no surprise. Over the last four quarters, the company has beaten consensus EPS estimates two times. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Mirion Technologies doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Among the stocks in the Zacks Technology Services industry, SLB (SLB), is soon expected to post earnings of $0.51 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of -31.1%. This quarter's revenue is expected to be $8.72 billion, up 2% from the year-ago quarter. The consensus EPS estimate for SLB has been revised 6.5% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -1.35%. This Earnings ESP, combined with its Zacks Rank #4 (Sell), makes it difficult to conclusively predict that SLB will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Mirion Technologies, Inc. (MIR) : Free Stock Analysis Report SLB Limited (SLB) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research